Sponsors (58)
The bill directs multi-year federal attention and funding toward uterine fibroid research, data collection, and targeted outreach—likely improving diagnosis, treatment options, and equity for many women—while raising federal costs, creating administrative burdens, and risking narrowed treatment choices or uneven messaging if implementation and oversight are weak.
Women with uterine fibroids (and clinicians/researchers treating them) will see increased federal research investment and focus, likely accelerating development of better diagnostics, fertility‑preserving and less invasive treatments, and clinical trials.
Researchers, health systems, and outreach programs gain predictable, multi-year federal support (authorized for 2026–2030), enabling sustained studies, trials, and education rather than one‑off efforts.
Women—especially minority women—will receive better, targeted information about uterine fibroid prevalence and non‑hysterectomy treatment options, which can increase awareness, earlier care‑seeking, and access to fertility‑preserving care.
Taxpayers will face increased federal spending (including a specified $150 million discretionary cost over five years and additional authorized sums for outreach), raising budgetary costs.
Targeting federal research and program funds to fibroids may divert limited NIH/AHRQ resources from other diseases and scientific priorities, potentially slowing work on other conditions.
States, Medicaid agencies, and healthcare providers could incur additional administrative and reporting burdens to supply data, adopt guideline materials, and participate in outreach, imposing costs and staff workload.
Based on analysis of 7 sections of legislative text.
Directs HHS to expand research, collect Medicaid/CHIP data, run public education, and promote evidence‑based fibroid care; authorizes $30M/year for research (FY2026–2030).
Introduced July 15, 2025 by Yvette Diane Clarke · Last progress July 15, 2025
Requires the Department of Health and Human Services to expand and coordinate research, data collection, public education, and promotion of evidence-based care for uterine fibroids, with special attention to racial and ethnic disparities. Authorizes $30 million per year for research (FY2026–2030), directs HHS to build a Medicaid/CHIP data collection/reporting effort on fibroid care and costs, and funds public outreach and clinical education activities to increase awareness and non‑hysterectomy treatment options.